共 50 条
Treatment of severe scalp psoriasis: From the Medical Board of the National Psoriasis Foundation
被引:78
|作者:
Chan, C. Stanley
[1
]
Van Voorhees, Abby S.
[2
]
Lebwohl, Mark G.
[3
]
Korman, Neil J.
[5
,6
]
Young, Melodic
Bebo, Bruce F., Jr.
Kalb, Robert E.
[4
]
Hsu, Sylvia
[1
]
机构:
[1] Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA
[5] Case Western Reserve Univ, Univ Hosp Cleveland, Dept Dermatol, Cleveland, OH 44106 USA
[6] Case Western Reserve Univ, Univ Hosp Cleveland, Murdough Family Ctr Psoriasis, Cleveland, OH 44106 USA
关键词:
CLOBETASOL PROPIONATE FOAM;
TAZAROTENE 0.1-PERCENT GEL;
PLAQUE PSORIASIS;
CALCIPOTRIOL SOLUTION;
BETAMETHASONE;
17-VALERATE;
DOVOBET(R) OINTMENT;
CLINICAL-EVALUATION;
DOUBLE-BLIND;
COAL-TAR;
EFFICACY;
D O I:
10.1016/j.jaad.2008.11.890
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Background The scalp is the most commonly affected part of the body in patients with psoriasis. Signs and symptoms of scalp psoriasis vary significantly for individual patients. Objective. A task force of the National Psoriasis Foundation was convened to evaluate treatment options. Our aim was to achieve a consensus for scalp psoriasis therapy. Methods: Reports in the medical literature were reviewed regarding scalp psoriasis therapy. Limitations: There is a paucity of evidence-based and double-blind Studies in the treatment of scalp psoriasis particularly for long-term therapy. Many of the studies in scalp psoriasis were designed to attain Food and Drug Administration approval for a medication and not to provide treatment guidance. Conclusions: The recommended short-term or intermittent therapy for scalp psoriasis is topical corticosteroids. The primary alternatives are topical retinoids, vitamin D analogues, and salicylic acid. Combination therapy has many advantages. The choice of an appropriate vehicle is crucial to increase patient compliance. While scalp psoriasis can often be adequately treated With topical therapy, recalcitrant disease may require more aggressive approaches, including systemic agents. (J Am Acad Dermatol 2009;60:962-71.)
引用
收藏
页码:962 / 971
页数:10
相关论文